MD3728207T2 - Chinazolinone ca inhibitori PARP14 - Google Patents
Chinazolinone ca inhibitori PARP14Info
- Publication number
- MD3728207T2 MD3728207T2 MDE20201102T MDE20201102T MD3728207T2 MD 3728207 T2 MD3728207 T2 MD 3728207T2 MD E20201102 T MDE20201102 T MD E20201102T MD E20201102 T MDE20201102 T MD E20201102T MD 3728207 T2 MD3728207 T2 MD 3728207T2
- Authority
- MD
- Moldova
- Prior art keywords
- quinazolinones
- parp14
- inhibitors
- parp14 inhibitors
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Prezenta invenţie se referă la chinazolinone şi la compuşi înrudiţi care sunt inhibitori ai PARP14 şi sunt utili, de exemplu, în tratamentul cancerului şi al bolilor inflamatorii.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608747P | 2017-12-21 | 2017-12-21 | |
| US201862691025P | 2018-06-28 | 2018-06-28 | |
| PCT/US2018/066700 WO2019126443A1 (en) | 2017-12-21 | 2018-12-20 | Quinazolinones as parp14 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3728207T2 true MD3728207T2 (ro) | 2023-09-30 |
Family
ID=65013795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20201102T MD3728207T2 (ro) | 2017-12-21 | 2018-12-20 | Chinazolinone ca inhibitori PARP14 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10562891B2 (ro) |
| EP (2) | EP4212515A1 (ro) |
| JP (2) | JP7381485B2 (ro) |
| KR (1) | KR20200103760A (ro) |
| CN (1) | CN111699176A (ro) |
| AU (2) | AU2018392616B2 (ro) |
| BR (1) | BR112020012197A2 (ro) |
| CA (1) | CA3085353A1 (ro) |
| DK (1) | DK3728207T3 (ro) |
| ES (1) | ES2941818T3 (ro) |
| FI (1) | FI3728207T3 (ro) |
| HR (1) | HRP20230183T1 (ro) |
| HU (1) | HUE061595T2 (ro) |
| IL (1) | IL275331A (ro) |
| LT (1) | LT3728207T (ro) |
| MD (1) | MD3728207T2 (ro) |
| MX (1) | MX2020006365A (ro) |
| PL (1) | PL3728207T3 (ro) |
| PT (1) | PT3728207T (ro) |
| RS (1) | RS64183B1 (ro) |
| SI (1) | SI3728207T1 (ro) |
| TW (1) | TWI813611B (ro) |
| WO (1) | WO2019126443A1 (ro) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3728207T3 (da) | 2017-12-21 | 2023-03-13 | Ribon Therapeutics Inc | Quinazolinoner som parp14-inhibitorer |
| WO2020046753A1 (en) | 2018-08-27 | 2020-03-05 | Oregon Health & Science University | Parp inhibitors for treating cancer and asthma |
| WO2021198191A1 (en) * | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| CN111423373B (zh) * | 2020-05-19 | 2024-01-19 | 瑞阳制药股份有限公司 | 硫酸羟氯喹的制备方法 |
| TW202241426A (zh) * | 2021-01-29 | 2022-11-01 | 美商律幫治療股份有限公司 | 治療發炎疾病之方法 |
| CN115260164B (zh) * | 2021-05-01 | 2024-03-26 | 杭州星鳌生物科技有限公司 | 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用 |
| WO2023154338A1 (en) * | 2022-02-09 | 2023-08-17 | Ribon Therapeutics, Inc. | Solid forms of a parp14 inhibitor |
| CN114634496B (zh) * | 2022-02-27 | 2024-04-19 | 复旦大学 | 吲哚酮取代-1,3-噻唑烷酮类衍生物及其制备方法和应用 |
| US20240051946A1 (en) | 2022-07-29 | 2024-02-15 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| WO2024026081A1 (en) | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607506B1 (fr) | 1986-12-02 | 1989-01-06 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| GB0030708D0 (en) | 2000-12-15 | 2001-01-31 | Imperial College | Single channel proteomics concepts |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| ES2279446T3 (es) | 2003-08-15 | 2007-08-16 | MERCK & CO., INC. | Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina. |
| UY29161A1 (es) | 2004-10-15 | 2006-04-28 | Bayer Pharmaceuticals Corp | Nuevos heterociclos |
| GB0914767D0 (en) | 2009-08-24 | 2009-09-30 | Sterix Ltd | Compound |
| CA2772188A1 (en) | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
| WO2013091773A1 (en) | 2011-12-22 | 2013-06-27 | Merck Patent Gmbh | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| WO2014009872A1 (en) * | 2012-07-09 | 2014-01-16 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| ES2632988T3 (es) * | 2013-07-31 | 2017-09-18 | Merck Patent Gmbh | Derivados de oxoquinazolinil-butanamida |
| WO2015073818A1 (en) | 2013-11-14 | 2015-05-21 | The Brigham And Women's Hospital, Inc. | Parp9 and parp14 as key regulators of macrophage activation |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| ME03763B (me) | 2014-04-23 | 2021-04-20 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
| WO2017042380A1 (en) | 2015-09-11 | 2017-03-16 | Universite De Lille 2 Droit Et Sante | Novel 5-amino-2-thioimidazole compounds and their use |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| GB201615282D0 (en) | 2016-09-08 | 2016-10-26 | Univ Bath | Tankyrase inhibitors |
| JP7260521B2 (ja) | 2017-07-12 | 2023-04-18 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | タウタンパク質分解の化合物 |
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| DK3728207T3 (da) | 2017-12-21 | 2023-03-13 | Ribon Therapeutics Inc | Quinazolinoner som parp14-inhibitorer |
| US20200407700A1 (en) | 2018-02-26 | 2020-12-31 | President And Fellows Of Harvard College | Compositions of parp14 modulators and/or mutants and therapeutic use thereof |
| WO2020046753A1 (en) | 2018-08-27 | 2020-03-05 | Oregon Health & Science University | Parp inhibitors for treating cancer and asthma |
| AU2020296063A1 (en) * | 2019-06-19 | 2021-12-23 | Ribon Therapeutics, Inc. | Targeted protein degradation of PARP14 for use in therapy |
| TW202241426A (zh) | 2021-01-29 | 2022-11-01 | 美商律幫治療股份有限公司 | 治療發炎疾病之方法 |
| WO2023154338A1 (en) * | 2022-02-09 | 2023-08-17 | Ribon Therapeutics, Inc. | Solid forms of a parp14 inhibitor |
-
2018
- 2018-12-20 DK DK18833588.9T patent/DK3728207T3/da active
- 2018-12-20 EP EP22212226.9A patent/EP4212515A1/en active Pending
- 2018-12-20 TW TW107146131A patent/TWI813611B/zh active
- 2018-12-20 ES ES18833588T patent/ES2941818T3/es active Active
- 2018-12-20 SI SI201830904T patent/SI3728207T1/sl unknown
- 2018-12-20 MX MX2020006365A patent/MX2020006365A/es unknown
- 2018-12-20 FI FIEP18833588.9T patent/FI3728207T3/fi active
- 2018-12-20 JP JP2020554054A patent/JP7381485B2/ja active Active
- 2018-12-20 LT LTEPPCT/US2018/066700T patent/LT3728207T/lt unknown
- 2018-12-20 KR KR1020207021282A patent/KR20200103760A/ko not_active Application Discontinuation
- 2018-12-20 PT PT188335889T patent/PT3728207T/pt unknown
- 2018-12-20 HU HUE18833588A patent/HUE061595T2/hu unknown
- 2018-12-20 BR BR112020012197-5A patent/BR112020012197A2/pt unknown
- 2018-12-20 CN CN201880088833.4A patent/CN111699176A/zh active Pending
- 2018-12-20 CA CA3085353A patent/CA3085353A1/en active Pending
- 2018-12-20 MD MDE20201102T patent/MD3728207T2/ro unknown
- 2018-12-20 HR HRP20230183TT patent/HRP20230183T1/hr unknown
- 2018-12-20 PL PL18833588.9T patent/PL3728207T3/pl unknown
- 2018-12-20 EP EP18833588.9A patent/EP3728207B1/en active Active
- 2018-12-20 US US16/227,132 patent/US10562891B2/en active Active
- 2018-12-20 WO PCT/US2018/066700 patent/WO2019126443A1/en active Application Filing
- 2018-12-20 AU AU2018392616A patent/AU2018392616B2/en active Active
- 2018-12-20 RS RS20230284A patent/RS64183B1/sr unknown
-
2020
- 2020-01-06 US US16/734,840 patent/US11008308B2/en active Active
- 2020-06-14 IL IL275331A patent/IL275331A/en unknown
-
2021
- 2021-04-14 US US17/230,099 patent/US11958837B2/en active Active
-
2023
- 2023-09-19 AU AU2023233066A patent/AU2023233066A1/en active Pending
- 2023-11-02 JP JP2023188422A patent/JP2024023224A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3728207T2 (ro) | Chinazolinone ca inhibitori PARP14 | |
| MD3788040T2 (ro) | Piridazinone în calitate ca inhibitori de PARP7 | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| PH12019502810A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| EA201691114A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
| MD3368541T2 (ro) | Compoziții și procedee de inhibare a activității arginazei | |
| MD3390395T2 (ro) | Compuși utili ca inhibitori ai kinazei | |
| EA201791866A1 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
| CY1121653T1 (el) | C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201892714A1 (ru) | Имидазолиновые соединения в качестве ингибиторов эластазы нейтрофилов человека | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| EA202091542A1 (ru) | Хиназолиноны в качестве ингибиторов parp14 | |
| EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств | |
| EA202190877A1 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr |